GenoMe (genometest.eu) will navigate you in complex space of DNA analysis and Virtual Doctor give you proposal of diagnostics testing. Multilanguage (ENG,DE,FR,POL) web-based service that helps you read and understand your DNA and your future offspring. After providing a saliva sample using an at-home kit, you can use our service to shed new light on your inherited conditions and traits. Combine your result with your partner to show genetic background of your future offspring and learn what your children can inherit. You can also find your genetically matched partner on our portal Genmatch.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MONSANTO AND DOW AGROSCIENCES ANNOUNCE GLOBAL LICENSING AGREEMENT ON EXZACT PRECISION TECHNOLOGY GENOME-EDITING PLATFORM

Dow AgroSciences | October 03, 2016

news image

Monsanto Company (NYSE: MON) and Dow AgroSciences LLC, a wholly-owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced today that the companies have reached a non-exclusive global option and licensing agreement on Dow AgroSciences’ EXZACT™ Precision Technology® Platform for research and commercial development of new crop solutions across Monsanto Company’s research portfolio....

Read More

IQ4I RESEARCH & CONSULTANCY PUBLISHED A NEW REPORT ON “GENOME EDITING GLOBAL MARKET – FORECAST TO 2022”

einnews | March 01, 2017

news image

Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes and are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo a...

Read More

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

news image

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More

STEM CELL MODELS OF HUMAN SPINE DEVELOPMENT UNVEILED

Drug Target Review | January 15, 2020

news image

Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...

Read More
news image

MONSANTO AND DOW AGROSCIENCES ANNOUNCE GLOBAL LICENSING AGREEMENT ON EXZACT PRECISION TECHNOLOGY GENOME-EDITING PLATFORM

Dow AgroSciences | October 03, 2016

Monsanto Company (NYSE: MON) and Dow AgroSciences LLC, a wholly-owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced today that the companies have reached a non-exclusive global option and licensing agreement on Dow AgroSciences’ EXZACT™ Precision Technology® Platform for research and commercial development of new crop solutions across Monsanto Company’s research portfolio....

Read More
news image

IQ4I RESEARCH & CONSULTANCY PUBLISHED A NEW REPORT ON “GENOME EDITING GLOBAL MARKET – FORECAST TO 2022”

einnews | March 01, 2017

Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes and are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo a...

Read More
news image

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More
news image

STEM CELL MODELS OF HUMAN SPINE DEVELOPMENT UNVEILED

Drug Target Review | January 15, 2020

Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...

Read More